Patents by Inventor Hiromasa Miyaji
Hiromasa Miyaji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100303766Abstract: A cell having excellent migration ability and engraftment ability to tissues is required for the restoration and the like of damaged tissues making use of a hematopoietic stem cell transplantation or a stem cell transplantation. By the present invention, a cell population having excellent migration ability and engraftment ability to tissues, a pharmaceutical preparation comprising said cell and a transplantation method of said cell are provided. The cell of the present invention is useful for hematopoietic stem cell transplantation and restoration of damaged tissues using stem cell transplantation and the like.Type: ApplicationFiled: August 8, 2008Publication date: December 2, 2010Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Hiromasa MIYAJI, Masahiro IKKAKU, Hidetaka SATO
-
Publication number: 20080044425Abstract: The present invention relates to a novel phospholipase A2 polypeptide, DNA encoding the polypeptide, a vector comprising the DNA, a transformant transformed with the vector, and a process for producing the phospholipase A2 polypeptide. The present invention also relates to a method of utilizing the polypeptide, e.g., a method of screening for a compound having agonist or antagonist activity by using the polypeptide or an antibody to the polypeptide, and a pharmaceutical comprising the polypeptide or an antibody to the polypeptide. The present invention further relates to a polypeptide inhibiting the phospholipase A2 activity of a phospholipase A2 polypeptide (hereinafter referred to as inhibitor polypeptide), DNA encoding the inhibitor polypeptide, a vector comprising the DNA encoding the inhibitor polypeptide, a transformant transformed with the vector, a pharmaceutical comprising the inhibitor polypeptide, and a process for producing the inhibitor polypeptide.Type: ApplicationFiled: July 27, 2007Publication date: February 21, 2008Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Hiromasa Miyaji, Motoko Haruoka, Hiroyuki Nagata, Toshio Ota, Ayako Kawabata, Sumio Sugano, Yusuke Nakamura
-
Patent number: 7258855Abstract: The present invention relates to a novel phospholipase A2 polypeptide, DNA encoding the polypeptide, a vector comprising the DNA, a transformant transformed with the vector, and a process for producing the phospholipase A2 polypeptide. The present invention also relates to a method of utilizing the polypeptide, e.g., a method of screening for a compound having agonist or antagonist activity by using the polypeptide or an antibody to the polypeptide, and a pharmaceutical comprising the polypeptide or an antibody to the polypeptide. The present invention further relates to a polypeptide inhibiting the phospholipase A2 activity of a phospholipase A2 polypeptide (hereinafter referred to as inhibitor polypeptide), DNA encoding the inhibitor polypeptide, a vector comprising the DNA encoding the inhibitor polypeptide, a transformant transformed with the vector, a pharmaceutical comprising the inhibitor polypeptide, and a process for producing the inhibitor polypeptide.Type: GrantFiled: September 19, 2001Date of Patent: August 21, 2007Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hiromasa Miyaji, Motoko Haruoka, Hiroyuki Nagata, Toshio Ota, Ayako Kawabata, Sumio Sugano, Yusuke Nakamura
-
Publication number: 20070073043Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.Type: ApplicationFiled: September 19, 2005Publication date: March 29, 2007Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Publication number: 20060252679Abstract: The present invention provides an agent for prevention and/or treatment of itching comprising a substance capable of suppressing the function involved in signal transduction of GPR4 as an active ingredient. It also provides a nitrogen-containing tricyclic compound represented by the formula (I) or a quaternary ammonium salt thereof, or a pharmaceutically acceptable salt thereof; [wherein R1 represents substituted or unsubstituted lower alkyl, etc.; R2 represents hydrogen, substituted or unsubstituted lower alkyl, etc.; R3 and R4 are the same or different and each represents hydrogen, lower alkyl, etc.; n represents 0 or 1; X represents —(CH2)2—, etc.; and Y represents the formula (II); (wherein W represents CH or a nitrogen atom; Z1 and Z2 are the same or different and each represents hydrogen, substituted or unsubstituted lower alkyl, etc.; and Z3 represents hydrogen, substituted or unsubstituted lower alkyl, etc.Type: ApplicationFiled: August 22, 2003Publication date: November 9, 2006Inventors: Mayumi Saki, Hiromi Nonaka, Hiromasa Miyaji, Shunji Ichikawa, Chiemi Takashima, Tsutomu Matsumura, Hitoshi Arai, Katsutoshi Sasaki, Choei Kobatake, Yukihito Tsukumo, Kyoichiro Iida, Takeshi Kuboyama, Haruhiko Manabe
-
Publication number: 20060239999Abstract: The present invention provides an agent for prevention and/or treatment of asthma comprising a substance capable of suppressing the function involved in signal transduction of GPR4 as an active ingredient.Type: ApplicationFiled: August 22, 2003Publication date: October 26, 2006Inventors: Mayumi Saki, Hiromi Nonaka, Hiromasa Miyaji, Naoko Hiura, Haruhiko Manabe, Tsotomu Matsumura, Hitoshi Arai, Katsutoshi Sasaki, Cjoei Kobatake, Kyoichiro Iida, Takeshi Kuboyama
-
Publication number: 20060111368Abstract: [wherein n represents an integer of from 1 to 4, R1 represents substituted or unsubstituted lower alkyl, —C(?Y)R9 or the like, R2 represents a hydrogen atom, substituted or unsubstituted lower alkyl or the like, R3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group or the like, and R4 represents halogen or the like.]A phosphodiesterase 10A inhibitor which comprises a quinoline derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient is provided.Type: ApplicationFiled: June 26, 2003Publication date: May 25, 2006Applicant: Kyowa Hakko Kogyo Co., Ltd.Inventors: Naoto Osakada, Motoko Haruoka, Ken Ikeda, Shinichiro Toki, Hiromasa Miyaji, Junichi Shimada
-
Patent number: 7045129Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.Type: GrantFiled: June 12, 2002Date of Patent: May 16, 2006Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Publication number: 20060057139Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.Type: ApplicationFiled: October 25, 2005Publication date: March 16, 2006Applicant: KYOWA HAKKO KOGYO CO., LTDInventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Publication number: 20060058512Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.Type: ApplicationFiled: September 19, 2005Publication date: March 16, 2006Applicant: KYOWA HAKKO KOGYO CO., LTDInventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Patent number: 6965024Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of said humanized chimera antibody, are disclosed.Type: GrantFiled: October 8, 2002Date of Patent: November 15, 2005Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Publication number: 20040014089Abstract: The present invention relates to a novel phospholipase A2 polypeptide, DNA encoding the polypeptide, a vector comprising the DNA, a transformant transformed with the vector, and a process for producing the phospholipase A2 polypeptide. The present invention also relates to a method of utilizing the polypeptide, e.g., a method of screening for a compound having agonist or antagonist activity by using the polypeptide or an antibody to the polypeptide, and a pharmaceutical comprising the polypeptide or an antibody to the polypeptide. The present invention further relates to a polypeptide inhibiting the phospholipase A2 activity of a phospholipase A2 polypeptide (hereinafter referred to as inhibitor polypeptide), DNA encoding the inhibitor polypeptide, a vector comprising the DNA encoding the inhibitor polypeptide, a transformant transformed with the vector, a pharmaceutical comprising the inhibitor polypeptide, and a process for producing the inhibitor polypeptide.Type: ApplicationFiled: March 19, 2003Publication date: January 22, 2004Inventors: Hiromasa Miyaji, Motoko Haruoka, Hiroyuki Nagata, Toshio Ota, Ayako Kawabata, Sumio Sugano, Yusuke Nakamura
-
Publication number: 20030166876Abstract: A process for the production of humanized chimera antibody, wherein the chimera antibody is produced easily without changing any of the amino acids of its mouse antibody variable region, which comprises the steps of: (1) constructing a cassette vector by inserting a cDNA coding for a heavy chain constant region of human antibody into an expression vector for animal cell use and establishing a cloning site in the upstream region of the heavy chain constant region of said cassette vector for inserting a cDNA which encodes a heavy chain variable region of nonhuman animal antibody; (2) digesting a cDNA coding for the heavy chain variable region of nonhuman animal antibody with restriction enzymes; (3) inserting said cDNA coding for the heavy chain variable region of nonhuman animal antibody into the cassette vector, using a synthetic DNA which comprises a base sequence corresponding to the 5′-end side of said heavy chain constant region of human antibody and a base sequence corresponding to the 3′-endType: ApplicationFiled: June 12, 2002Publication date: September 4, 2003Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Publication number: 20030095964Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of said humanized chimera antibody, are disclosed.Type: ApplicationFiled: October 8, 2002Publication date: May 22, 2003Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Patent number: 6495666Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.Type: GrantFiled: January 19, 2001Date of Patent: December 17, 2002Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Patent number: 6437098Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.Type: GrantFiled: January 5, 1999Date of Patent: August 20, 2002Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Publication number: 20020026036Abstract: A process for the production of humanized chimera antibody, wherein the chimera antibody is produced easily without changing any of the amino acids of its mouse antibody variable region, which comprises the steps of: (1) constructing a cassette vector by inserting a cDNA coding for a heavy chain constant region of human antibody into an expression vector for animal cell use and establishing a cloning site in the upstream region of the heavy chain constant region of said cassette vector for inserting a cDNA which encodes a heavy chain variable region of nonhuman animal antibody; (2) digesting a cDNA coding for the heavy chain variable region of nonhuman animal antibody with restriction enzymes; (3) inserting said cDNA coding for the heavy chain variable region of nonhuman animal antibody into the cassette vector, using a synthetic DNA which comprises a base sequence corresponding to the 5′-end side of said heavy chain constant region of human antibody and a base sequence corresponding to the 3′-endType: ApplicationFiled: January 19, 2001Publication date: February 28, 2002Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Patent number: 6027720Abstract: Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different amino acid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such plasmids, methods of producing the hG-CSF polypeptide derivatives using the microorganisms, a monoclonal antibody binding to the hG-CSF polypeptide derivative, and chemically modified hG-CSF or derivatives thereof are disclosed.Type: GrantFiled: July 13, 1994Date of Patent: February 22, 2000Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Tetsuro Kuga, Hiromasa Miyaji, Moriyuki Sato, Masami Okabe, Makoto Morimoto, Seiga Itoh, Motoo Yamasaki, Yoshiharu Yokoo, Kazuo Yamaguchi, Hajime Yoshida, Yoshinori Komatsu
-
Patent number: 5994518Abstract: Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different amino acid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such plasmids, methods of producing the hG-CSF polypeptide derivatives using the microorganisms, a monoclonal antibody binding to the hG-CSF polypeptide derivative, and chemically modified hG-CSF or derivatives thereof are disclosed.Type: GrantFiled: July 9, 1997Date of Patent: November 30, 1999Assignee: Kyowa Hakko Co., LtdInventors: Tetsuro Kuga, Hiromasa Miyaji, Moriyuki Sato, Masami Okabe, Makoto Morimoto, Seiga Itoh, Motoo Yamasaki, Yoshiharu Yokoo, Kazuo Yamaguchi, Hajime Yoshida, Yoshinori Komatsu
-
Patent number: 5866692Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of said humanized chimera antibody, are disclosed.Type: GrantFiled: May 31, 1995Date of Patent: February 2, 1999Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana